Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pharmacogenomic data for personalized medicines].

Hiroshi Yamazaki1

  • 1Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 12, 2005
PubMed
Summary

The FDA now accepts pharmacogenomic data for drug development. Key biomarkers like CYP2D6 and TPMT are crucial for personalized medicine, guiding drug metabolism and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam.

Drug metabolism and pharmacokinetics·2021
Same author

Impact of nitrogen compound variability of sewage treated water on N<sub>2</sub>O production in riverbeds.

Journal of environmental management·2021
Same author

Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources.

Drug metabolism and pharmacokinetics·2021
Same author

Hepatotoxicological potential of <i>P</i>-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models.

Xenobiotica; the fate of foreign compounds in biological systems·2021
Same author

Evaluation of domain of unknown function 1220 (DUF1220) for detection of human genome by quantitative polymerase chain reaction: Potential use in assessing the biodistribution of transplanted therapeutic human cells.

Drug metabolism and pharmacokinetics·2021
Same author

Associations between Socioeconomic Status, Social Participation, and Physical Activity in Older People during the COVID-19 Pandemic: A Cross-Sectional Study in a Northern Japanese City.

International journal of environmental research and public health·2021

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Biomarker Discovery

Context:

  • FDA guidance on pharmacogenomic data submission.
  • Cytochrome P450 2D6 (CYP2D6) and thiopurine S-methyltransferase (TPMT) identified as key biomarkers.
  • Increasing recognition of genetic variations in drug response.

Purpose:

  • Review current strategies for pharmacogenomic data utilization.
  • Highlight the role of biomarkers in drug development.
  • Discuss applications in personalized medicine.

Summary:

  • FDA guidance promotes pharmacogenomic data integration.
  • CYP2D6 and TPMT polymorphisms influence drug metabolism.
  • This review covers pharmacogenomic data in drug development and personalized therapies.

Impact:

  • Facilitates regulatory acceptance of pharmacogenomic data.
  • Enables more precise drug development pathways.
  • Advances the field of personalized medicine through genetic insights.

Related Experiment Videos